Novozymes finishes difficult 2019 burdened by bioenergy
The Danish enzyme producer landed an organic growth figure of -1 percent in 2019, significantly below the company's original guidance for the year. The company moreover initiates a share buyback program of EUR 200 million.
As expected, 2019 became a year of negative growth for Danish enzyme producer Novozymes, which saw organic growth of 1 percent in Q4 and thus finishes a year in which the firm's self-image as a high-growth company has taken its hardest blow yet.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
